ARA-290 is a research compound of growing interest for its non-haematopoietic activity at the innate repair receptor, making it a focus of tissue-protection and neuropathic pain research programs.
ARA-290 (also studied under the name Cibinetide) is an 11-amino-acid compound fragment derived from the helix-B surface of erythropoietin (EPO). Unlike full-length EPO, ARA-290 does not bind the classical erythropoietin receptor and does not stimulate red blood cell production. Instead, research indicates it selectively activates the innate repair receptor (IRR), a heterodimer of the EPO receptor and the beta common receptor (CD131), which is associated with tissue-protective and anti-inflammatory signalling rather than haematopoiesis.
What Makes ARA-290 Unique
Because ARA-290 spares the haematopoietic pathway, researchers can investigate EPO-related tissue repair signalling without the erythropoietic side effects associated with full-length EPO analogues. This selectivity has made it a preferred tool compound in models examining nerve regeneration, microvascular repair, and inflammatory signalling independent of blood cell production.
Key Research Areas
Preclinical literature has examined ARA-290 in models of diabetic peripheral neuropathy, small-fibre neuropathy, and corneal nerve density, with researchers tracking changes in nerve fibre regeneration and pain-related behavioural markers. Cardiovascular and microvascular research has explored its role in endothelial protection and ischaemia-reperfusion models. Additional research streams have investigated its anti-inflammatory profile in models of tissue injury and metabolic stress.
Research Protocols and Handling
Published research protocols investigating ARA-290 commonly use subcutaneous administration in animal models, with dosing and duration varying significantly by study design and research objective. Researchers should always refer to the specific literature relevant to their protocol rather than extrapolating dosing between study types.
Storage: lyophilised compound should be stored at -20°C and protected from light and moisture prior to reconstitution. Once reconstituted with bacteriostatic water, store refrigerated at 2-8°C and use within the timeframe indicated by your research protocol.
Product Details
Product: ARA-290
Quantity: 10mg per vial
Format: Lyophilised powder in a sealed vial
Purity: Refer to the batch-specific Certificate of Analysis (COA)
Intended Use: Research use only
Sourcing ARA-290 in Australia
Pure Glow Health supplies ARA-290 as a third-party tested, laboratory-grade research compound for qualified researchers across Australia, with fast Perth-metro dispatch and temperature-aware packaging. Every batch is supplied with its own Certificate of Analysis so researchers can verify purity before use.
Research Use Only
ARA-290 is intended strictly for laboratory and research purposes. It is not intended for human or veterinary use, diagnosis, treatment, cure, or prevention of any disease or medical condition. For research use only. Not for human consumption.
